Federal grants to Celdara Medical, LLC
Celdara Medical, LLC in Lebanon, New Hampshire received $18.1 million in federal grants from fiscal 2021 to 2025, across 14 awards. Its largest program was Allergy and Infectious Diseases Research, with $7.8 million. In fiscal 2025 it was awarded $3.7 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$18.1 million
- Awards14
- Awarded in FY 2025$3.7 million
- Largest award$2.9 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 4 | $2.3 million |
| FY 2022 | 10 | $3.4 million |
| FY 2023 | 7 | $4.7 million |
| FY 2024 | 5 | $4.1 million |
| FY 2025 | 5 | $3.7 million |
Programs that fund Celdara Medical, LLC
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 4 | $7.8 million |
| Cancer Treatment Research | 3 | $3.4 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 2 | $3.0 million |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 2 | $3.0 million |
| Aging Research | 1 | $648,000 |
| Cardiovascular Diseases Research | 1 | $285,689 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 14 | $18.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome - project summary rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with huma | Allergy and Infectious Diseases Research | March 1, 2023 | $2.9 million |
| Development of CM-CS1 car treg to treat amyotrophic lateral sclerosis (ALS) - summary amyotrophic lateral sclerosis (ALS) patients develop fatal paralysis as a result of progressive motor neuron loss in the brain and spinal cord. There are more than 5,000 new cases of als per year in the united stat | Extramural Research Programs in the Neurosciences and Neurological Disorders | September 18, 2023 | $2.3 million |
| Anti-hiapp for the preservation of pancreatic function in type 2 diabetes - project summary according to the american diabetes association, type 2 diabetes mellitus (T2D) affects at least 30 million americans and is a major unmet public health concern with an annual cost in the united states of over | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 22, 2022 | $2.3 million |
| Development of CM-IAV1 for treatment of high-risk pandemic influenzas - project summary health and human services (HHS) and the biomedical advanced research and development authority (BARDA) have suggested a severe pandemic influenza outbreak is the greatest current threat to national and global sec | Allergy and Infectious Diseases Research | April 25, 2022 | $2.3 million |
| Development of CM-SV1, a monoclonal antibody treatment for sudan virus | Allergy and Infectious Diseases Research | March 1, 2021 | $2.0 million |
| Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas - project summary cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches for neoplastic diseases has been developed. However, due to thei | Cancer Treatment Research | September 8, 2021 | $1.8 million |
| Development of CM-HZ01 as a NON-ALPHA-IL2 therapeutic for the treatment of metastatic melanoma - summary melanoma incidence is increasing at an alarming rate; as the deadliest of all skin cancers, it is estimated that one person, every hour of every day, dies of melanoma. INTERLEUKIN-2 (IL-2) was th | Cancer Treatment Research | December 24, 2024 | $1.2 million |
| Mitigation of acute kidney injury (AKI) using the polymer prodrug, APP-103TM | Diabetes, Digestive, and Kidney Diseases Extramural Research | November 5, 2020 | $747,225 |
| KV2.1-TARGETED first in class neuroprotective therapeutic for acute ischemic stroke - project summary acute ischemic stroke (AIS) impacts 795,000 americans per year, leaving 90% of patients with chronic disability. Prevalent cases of ais in the us were estimated at 6.7M in 2017, translating to 6M am | Extramural Research Programs in the Neurosciences and Neurological Disorders | September 19, 2023 | $653,080 |
| Alzheimer's-focused celdara medical high-potential entrepreneurial fellowship program (a-chef) - while the majority of biomedical scientists end up in professions outside of academia, most receive little-to-no training in preparation for this transition. Here, we seek to establish a comprehensive tr | Aging Research | August 1, 2022 | $648,000 |
Questions people ask
How much federal grant money does Celdara Medical, LLC get?
$18.1 million in 14 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Celdara Medical, LLC the most?
The Department of Health and Human Services, with $18.1 million in 14 awards.
What is Celdara Medical, LLC's largest federal grant?
$2.9 million under Allergy and Infectious Diseases Research, with its first action in the period on March 1, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Celdara Medical, LLC?
Its largest are Allergy and Infectious Diseases Research, Cancer Treatment Research and Diabetes, Digestive, and Kidney Diseases Extramural Research.
Other grant recipients in Lebanon
- Dartmouth-Hitchcock Clinic
- Mary Hitchcock Memorial Hospital
- Doseoptics LLC
- Insight Surgical Technologies Inc.
- West Central Services, Inc.
- City of Lebanon
- Upper Valley Lake Sunapee Regional Planning Commission
- Bionic Skins LLC
Largest federal grant recipients in New Hampshire · Federal grants in New Hampshire